Distrust in Vaccines: The Hidden Risk for Biopharma Growth

Good morning, ! This week we’re diving into the distrust of vaccines and how it impacts Biopharma.GTCR  acquires Zentiva for €4.1B, AI still needs penetration growth in Healthcare, and median deal size in Healthtech grew by 39% in 2024 compared to the previous year.

Want to advertise in Healthcare 150? Check out our self-serve ad platform, here.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

DATA DIVE

Trust Gaps Are Repricing Biopharma

Biopharma’s global valuation outlook is no longer just a function of pipeline strength or pricing power—it’s now tied to vaccine trust and public perception risk. According to new analysis, 30% of the global population now actively distrusts vaccines, a structural headwind for commercial rollouts, especially in politically polarized or cost-sensitive markets.

In the U.S., 50% trust vs. 25% distrust splits the market into volatility-prone halves, complicating revenue forecasting and raising SG&A spend through lobbying and litigation. The U.K.’s 62% distrust rate all but assures tighter regulatory scrutiny and margin compression. India (89% distrust) and South Africa (65%) present even steeper commercial hurdles, requiring biopharma to lean heavily on state procurement or donor-funded distribution—routes that rarely offer scale or profitability.

Investor bottom line: Vaccine distrust isn’t just a PR issue—it’s a WACC inflator and cash flow depressor. It directly impacts TAM forecasts, elongates adoption cycles, and limits premium multiple upside. For PE and institutional investors, exposure to retail-facing or vaccine-dependent portfolios now carries embedded sentiment risk.

Mitigation playbook: Stress-test revenue models for booster erosion, bet on B2B-aligned firms, and prioritize assets with strong government or NGO ties. In this environment, brand trust may be worth more than IP.

Read the Full Report HERE

TREND OF THE WEEK

The AI Trust Gap in Healthcare

AI is here—but patients and professionals trust it very differently. According to the Future Health Index, doctors overwhelmingly back AI in tasks like medical notes (87%) and triaging urgent cases (81%), but patients trail far behind (64% and 63%, respectively). Where’s the comfort zone? Check-ins and scheduling (76%), where trust nearly matches professionals (84–88%). The issue isn’t capability—it’s trust at the bedside. Patients see AI as helpful for logistics, but hesitate when algorithms creep into diagnosis or treatment. For innovators, the challenge is clear: success in healthcare AI won’t just be about precision—it’ll hinge on transparency, communication, and maintaining the human touch. (More)

PRESENTED BY EVERY.IO

The back office, built for founders

We’ve worked with over 800 startups—from first-time founders at pre-seed to fast-moving teams raising Series A and beyond—and we’d love to help you navigate whatever’s next.

Here’s how we’re willing to help you:

• Incorporating a new startup? We’ll take care of it—no legal fees, no delays.

• Spending at scale? You’ll earn 3% cash back on every dollar spent with our cards.

• Transferring $250K+? We’ll add $2,000 directly to your account.

Get started today.

HEALTHTECH CORNER

Bigger Checks, Bigger Bets

Digital Health isn’t slowing down—it’s bulking up. The median deal size hit $5.3M in 2024, a 39% jump from last year and the highest on record. After years of hovering in the $3.7M–$4M range, investors are clearly writing bigger checks. Why? Confidence that healthtech is no longer just about ideas, but about scalable, revenue-ready platforms. With hospitals strained by cost pressures and workforce shortages, tools that drive efficiency and patient engagement are commanding premiums. The bet here isn’t small pilots; it’s real adoption at scale. Translation: investors are moving past shiny demos and backing companies that can deliver both clinical outcomes and financial returns. (More)

TOGETHER WITH REMOFIRST

International HR and payroll in 185+ countries

Growing your team outside your HQ country? RemoFirst helps you employ anywhere, with EOR services available in 185+ countries.

International HR and payroll for global employees and contractors— without setting up a local entity.

Start hiring globally

DEAL OF THE WEEK

GTCR Drops €4.1B on Zentiva in European Generics Power Play

Private equity giant GTCR has agreed to acquire Czech-based Zentiva from Advent International for €4.1 billion ($4.8 billion)—marking one of the largest European healthcare buyouts of 2025.

Zentiva, a maker of generic and OTC drugs, has grown into a pan-European force under Advent, which bought it from Sanofi in 2018 for €1.9 billion. That bet now looks prescient: Zentiva has expanded across 30+ countries, doubled its valuation, and attracted attention from global bidders including India’s Aurobindo Pharma.

This transaction signals private equity’s deepening interest in generic pharmaceuticals—a sector with tight margins but predictable cash flows, high volume, and strategic M&A potential. GTCR’s move aligns with broader consolidation trends, as funds look to assemble continental-scale platforms capable of competing with Teva and Viatris.

Why it matters: In a market jittery over biotech risk and regulatory uncertainty, generics offer an underappreciated hedge—essential products with global cost-cutting tailwinds. For GTCR, Zentiva is not just a €4B asset—it’s a launchpad. (More)

REGIONAL FOCUS

Global Oncology Market: Who’s Driving, Who’s Drafting?

North America is still the pole position holder in oncology drug revenue, thanks to deep R&D pockets and a taste for early adoption. But the pit crew is expensive—regulatory speed bumps and pricing pressure abound. Europe follows with solid infrastructure but gets tripped up by fragmented reimbursement. Asia-Pacific? It’s the fastest-growing lap, fueled by sheer volume and biopharma bets in China, India, Korea, and Japan. Meanwhile, Latin America and Middle East & Africa are steadily advancing from the back of the grid, gaining momentum as investment and access improve. Projected global oncology drug spend is set to almost double to ~$409B by 2028. (More)

INTERESTING ARTICLES

"Success seems to be connected with action. Successful people keep moving. They make mistakes, but they don't quit."

Conrad Hilton